United States · FDA National Drug Code directory
Ocrevus Zunovo
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50242-554_7075d975-19b9-497b-9657-3a99a527ffd4
- Product NDC
- 50242-554
- Form
- INJECTION, SOLUTION
- Composition / generic term
- ocrelizumab and hyaluronidase
- Labeler
- Genentech, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240913
- Source listing expiry
- 20271231
Source-listed ingredients
- OCRELIZUMAB — 920 mg/23mL
- HYALURONIDASE (HUMAN RECOMBINANT) — 23000 U/23mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-USE in 1 CARTON (50242-554-01) / 23 mL in 1 VIAL, SINGLE-USE · 50242-554-01
- 1 VIAL, SINGLE-USE in 1 CARTON (50242-554-86) / 23 mL in 1 VIAL, SINGLE-USE · 50242-554-86
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →